These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 14747047)

  • 1. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
    Walczak JR; Carducci MA;
    Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone therapy in advanced prostate cancer.
    Forster TH; Stoffel F; Gasser TC
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract]   [Full Text] [Related]  

  • 4. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovations in the systemic therapy of prostate cancer.
    Shepard DR; Raghavan D
    Nat Rev Clin Oncol; 2010 Jan; 7(1):13-21. PubMed ID: 19997075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ; Small EJ
    Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.
    Oh WK
    Urol Oncol; 2003; 21(3):229-34. PubMed ID: 12810211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B
    Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine therapy of prostate cancer.
    Bare RL; Torti FM
    Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer: The androgen receptor remains front and centre.
    Saylor PJ
    Nat Rev Clin Oncol; 2013 Mar; 10(3):126-8. PubMed ID: 23381000
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant androgen suppression and external beam radiation therapy.
    Zietman AL; Smith CT
    Front Radiat Ther Oncol; 2002; 36():87-98. PubMed ID: 11842759
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
    Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
    Gomella LG; Zeltser I; Valicenti RK
    Urology; 2003 Dec; 62 Suppl 1():46-54. PubMed ID: 14747041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
    Halabi S; Small EJ; Vogelzang NJ; Barrier RC; George SL; Gilligan TD
    Urology; 2004 Aug; 64(2):212-7. PubMed ID: 15302462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.